CVS (chorionic villus sampling) is a test carried usually carried out between the 11th and 14th week of pregnancy, in which a few cells of the placenta are removed for biochemical or genetic testing. This is most commonly to check a fetus for conditions such as Down’s syndrome and other chromosomal or genetic disorders.
Gene expression in the placenta is different for male and female fetuses during the first trimester...
A Texas court has awarded $100 million more damages to a company whose patents for non-invasive prenatal testing technology were infringed by a competitor...
A new rapid test can detect missing or extra chromosomes as part of prenatal and fertility care...
Prenatal genetic test results need to be communicated better, according to the US Food and Drug Administration...
A single blood drop, taken without your consent, can be life-changing...
A long-running court case over non-invasive prenatal testing patents has been settled...
Non-invasive prenatal testing (NIPT) was first introduced in 2011, when breakthroughs in sequencing technology allowed the analysis of cell-free fetal DNA(cffDNA) in maternal blood to detect genetic abnormalities in the foetus, such as trisomy 21 (Down
Jnetics and Chana shared their first joint event, with leading experts speaking about Jewish genetic disorder carrier screening, fertility advice and the reproductive options available to ensure genetic disorders are not passed onto future children...
The UK Patents Court has ruled that two separate non-invasive prenatal tests infringe patents licensed by the US firm Illumina...
Join our list to stay up-to-date on all the latest developments in the fields of human fertility and genomics.
